Media coverage about ACASTI PHARM-TS (CVE:APO) has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ACASTI PHARM-TS earned a coverage optimism score of 2.60 on their scale. InfoTrie also gave news articles about the company an news buzz score of 4 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
ACASTI PHARM-TS (CVE:APO) last announced its quarterly earnings results on Wednesday, November 13th. The company reported C($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of C($0.13) by C$0.03.
Separately, B. Riley reiterated a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, August 28th.
Featured Story: What is the NASDAQ Stock Market?
Receive News & Ratings for ACASTI PHARM-TS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACASTI PHARM-TS and related companies with MarketBeat.com's FREE daily email newsletter.